John Young named Group President, Pfizer Innovative Health
Angela
Hwang named Group President, Pfizer Essential Health
NEW YORK--(BUSINESS WIRE)--
Pfizer Inc. (NYSE: PFE) today announced that Albert Bourla has been
named Chief Operating Officer effective January 1, 2018.
“The naming of a Chief Operating Officer comes at a time when our
business is strong as we continue to advance our strategy while also
managing a dynamic and challenging external environment, said Ian Read,
Pfizer Chairman and CEO.
"The addition of a COO will enable me to spend more time focusing on the
company's long term strategic direction, ensuring continued R&D
productivity and engaging with government policy and industry leaders on
key issues facing the future of the healthcare industry.”
Albert Bourla, 56, has been the Group President of Pfizer’s Innovative
Health Business since the beginning of 2016. Under his leadership
revenues for the Pfizer Innovative Health business grew 11%
operationally in 2016 and in the first nine months of 2017 have grown 9%
operationally. Prior to his current position Dr. Bourla was the Group
President for Pfizer’s Vaccines, Oncology and Consumer Healthcare
businesses where he was instrumental in building a strong and
competitive position in Oncology and expanded the company’s leadership
in vaccines.
Over the course of his career Dr. Bourla has held a number of senior
global positions across a range of businesses and geographies.
Read continued, “Albert is a proven and trusted leader with over two
decades of leadership experience and a demonstrated track record for
delivering strong business results. He possesses the right combination
of skills, knowledge, strengths and a deep commitment to Pfizer’s
culture that make him the clear choice to become Pfizer’s COO.”
As General Manager of the company’s Established Products Business Unit
he advanced the company’s efforts to build a strong post-patent business
by spear-heading efforts that maximized the lifecycle of key brands
following loss of exclusivity.
Prior to leading the Established Products business, Dr. Bourla was the
Area President for Pfizer’s Animal Health business across Europe,
Africa, and Asia Pacific where he successfully managed the integration
of Wyeth’s Animal Health Business (Fort Dodge) with Pfizer in these
global markets.
Dr. Bourla has significant scientific expertise. He is a Doctor of
Veterinary Medicine and holds a PhD degree in the Biotechnology of
Reproduction from the Veterinary School of Aristotle University.
Effective January 1, 2018 John Young, Group President, Pfizer Essential
Health becomes Group President, Pfizer Innovative Health. Angela Hwang,
Global President and General Manager for Pfizer Inflammation &
Immunology will succeed John Young as Group President, Pfizer Essential
Health.
Mr. Young has held a number of senior leadership positions across Pfizer
including as President of the Primary Care Business. He is a scientist
by training and has deep knowledge of the company’s innovative
biopharmaceutical portfolio having led the commercial and clinical
development of medicines in key therapeutic areas including
cardiovascular disease, diabetes and pain.
Mr. Young received a BSc in Biological Science from Glasgow University
and an MBA from Strathclyde Graduate Business School. He will report to
Dr. Bourla and will continue to be a member of the company’s Executive
Leadership Team.
Ms. Hwang joined the company in 1997 in the company’s Corporate
Strategic Planning and Policy Group. Her experience includes leadership
roles within the Innovative Health and Essential health businesses as
Global President Pfizer Inflammation and Immunology, Regional head for
U.S. Vaccines, Vice President of Emerging Markets for the Primary Care
business and Vice President of the U.S. Brands business within Essential
Health. In her current role she has been responsible for the growth of
products such as Xeljanz and Eucrisa and building a strong pipeline
around rheumatology, gastroenterology and dermatology.
Ms. Hwang received her Bachelor of Science in Microbiology and
Biochemistry from the University of Cape Town and a Masters of Business
Administration from Cornell University. She will become a member of the
company’s Executive Leadership team and will report to Dr. Bourla.
Additional members of the Pfizer Executive Leadership team reporting to
Dr. Bourla will be:
Kirsten Lund-Jurgensen – Executive Vice President and President
Pfizer Global Supply
Rod MacKenzie – Executive Vice President, Chief Development
Officer
Laurie Olson – Executive Vice President, Strategy and Commercial
Operations
In addition to Dr. Bourla, the following members of Pfizer’s Executive
Leadership team will continue to report to Ian Read:
Frank D’Amelio – Executive Vice President, Business Operations
and Chief Financial Officer
Mikael Dolsten – Executive Vice President and President,
Worldwide Research & Development
Chuck Hill – Executive Vice President, Worldwide Human Resources
Rady Johnson – Executive Vice President, Chief Compliance and
Risk Officer
Doug Lankler – Executive Vice President, General Counsel
Freda Lewis-Hall – Executive Vice President and Chief Medical
Officer
Sally Susman – Executive Vice President, Corporate Affairs
View source version on businesswire.com: http://www.businesswire.com/news/home/20171113005652/en/
Source: Pfizer Inc.